Cancer Trials Ireland > Resources > Conference Presentations

Conference Presentations

Conference Presentations for Cancer Trials Ireland Studies

Study Number: Short Name

2020 Conference Presentations

15-16: Flipper Albanell, J., M. T. M. Martinez, M. Ramos, M. O’Connor, L. De la Cruz-Merino, A. Santaballa Bertan, N. Martínez-Jañez, F. Moreno, I. Fernández Pérez, J. Alarcon Company, J. A. Virizuela Echaburu, J. De la Haba Rodríguez, P. Sánchez-Rovira, L. González-Cortijo, M. M. Margeli Vila, A. Sánchez Munoz, I. Garau Llinas, M. Casas, S. B. Montes & F. Rojo Todo (2020). “GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC)” Poster Presentation – ESMO (Ann Oncol 31, no 4 suppl; abstr LBA19).
15-49: NeoTRIP

 

 Bianchini, G., C-S. Huang, D. Egle, B. Bermejo, C. Zamagni, M. Thill, A. Anton, S. Zambelli, S. Russo, E. M. Cirelos, R. Greil, V. Semiglazov, M. A. Colleoni, C. M. Kelly, G. Mariani, L. Del Mastro, C. Smart, P. Valagussa, G. Viale & L. Gianni (2020). “Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial” Oral Presentation – ESMO (Ann Oncol 31, no 4 suppl; abstr LBA13).
10-06: TROG DCIS

 

 Chua, B. H., E. Link, I. Kunkler, I. Olivotto, A. H. Westenberg, T. Whelan and G. Gruber (2020). “A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)” Oral Presentation – SABCS (abstr GS2-04).  
11-29: ICON 8B

 

 Clamp, A. R., E. C. James, I. McNeish, A. Dean, J-W. Kim, D. M. O’Donnell, J. Hook, D. Gallardo-Rincon, C. Coyle, S. Blagden, J. D. Brenton, R. Naik, T. J. Perren, S. Sundar, A. Cook, J. Badrock, A. M. Awart, M. K. Parmar, R. S. Kaplan, J. A. Ledermann (2020). “ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment” Oral Presentation – ESMO (Ann Oncol 31, no 4 suppl; abstr 805O).
15-42: LOXO 101 Study

 

 Drilon, A. E., A. F. Farago, D. S-W. Tan, S. Kummar, R. S. McDermott, J. Berlin, J. D. Patel, M. S. Brose, S.Leyvraz, M. Tahara, B. M. Soloman, J. A. Reeves, M. M. Fellous, N. Brega, B. H. Childs, U. N. Lassen & D. S. Hong (2020). “Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set” Poster Presentation – ASCO Annual Meeting (J Clin Oncol 38: 2020 (no. 15 suppl; abstr 3610)). 
12-43: TRIO 022/ PALOMA-2

 

 Gelmon, K., J. M Walshe, R. Mahtani, A. A. Joy, M. Karuturi, P. Neven, D. R. Lu, S. Kim, P. Schnell, E. Bananis and L. Schwartzburg (2020). “Efficacy and safety of palbociclib (PAL) in patients (pts) with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with preexisting conditions: A post hoc analysis of PALOMA-2” Poster Presentation – SABCS (abstr PS10-14).
15-42: LOXO 101 Study

 

 Kummar, S., C. M. Van Tilburg, C. M. Albert, J. Berlin, A. F. Farago, R. S. McDermott, S. S Bielack, F. P. Doz, S. G. DuBois, U. N. Lassen, S. Leyvraz, L. Mascarenhas, R. Nagasubramanian, K. N. Keating, C. Chirila, B. H. Childs, T. W. Laetsch, A. E. Drilon & D. S. Hong (2020). “Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population” Poster Presentation – ASCO Annual Meeting (J Clin Oncol 38: 2020 (no. 15 suppl; abstr 3614)).
12-38: TRI-LARC

 

 Lee, C. L., S. Toomey, B. O’Neill and B. T. Hennessy (2020). “Serial ctDNA (circulating tumour DNA) for detection of genomic changes during neoadjuvant chemoradiotherapy (NACRT) in locally advanced rectal cancer (LARC)” Poster Presentation – ESMO (Ann Oncol 31, no 4 suppl; abstr 430P).
14-11: PENELOPE-B

 

 Loibl, S., F. Marmé, M. Martin, M. Untch, H. Bonnefoi, S-B. Kim, H. Bear, N. McCarthy, M. M. Olivé, K. Gelmon, J. G. Sáenz, C. M. Kelly, T. Reimer, M. Toi, H. S. Rugo, S. Seiler, V. Nekljudova, C. Denkart, M. Gnant, A. Makris, N. Burchardi and G. von Minckwitz (2020). “Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B” Oral Presentation – SABCS (abstr GS1-02).
15-34: Recurrence Score

 

 McSorley, L. M., F. Al Rahbi, M. Tharmabala, D. Evoy, J. G. Geraghty, R. Prichard, J. Rothwell, D. McCartan, E. McDermott, M. M. Keane, J. Kennedy, S. O’Reilly, S. Millen, J. Crown, L. M. Smyth, C. M. Kelly, C. Quinn & J. M. Walshe (2020). “Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland” Poster Presentation – ASCO Annual Meeting (J Clin Oncol 38: 2020 (no 15 suppl; abstr 540)).
16-04: PRIMA

 

 Mirza, M. R., A. Gonzalez Martin, W. Graybill, D. M. O’Malley, L. Gaba, O-W. S. Yap, E. M. Guerra, P. G. Rose, J. F. Baurain, S. A. Ghamande, H. Denys, E. Prendergast, C. Pisano, P. Follana, K. Baumann, P. Calvert, J. Korach, Y. Li, D. Gupta, B. J. Monk (2020). “Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study” Poster Presentation – ASCO Annual Meeting (J Clin Oncol 38: 2020 (no. 15 suppl; abstr 6050)).
16-04: PRIMA

 

 Monk, B. J., I. Romero, W. Graybill, C. Churruca, D. M. O’Malley, B. Lund, O-W. S. Yap, J-F. Baurain, P. G. Rose, H. Denys, S. A. Ghamande, C. Pisano, M. Fabbro, E. I. Braicu, P. Calvert, A. Amit, E. Prendergast, A. Milton, Z-Y. Zhang, A. Gonzalez Martin (2020). “Niraparib exposure-response relationship in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)” Poster Presentation – ASCO Annual Meeting (J Clin Oncol 38: 2020 (no. 15 suppl; abstr 6051)).
19-32: DASL HiCAP

 

 Niazi, T., S. Williams, I. D. Davis, M. R. Stockler, A. J. Martin, K. Bracken, F. Roncolato, M. McJannett, L. Horvath, S. Sengupta, S. Hughes, R. McDermott, J. W. Catto, P. Kelly, N. Vapiwala, W. R. Parulekar, S. Morgan, R. A. Rendon & C. Sweeney (2020). “DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation” Poster Presentation – ESMO (Ann Oncol 31, suppl 4; abstr 694TiP).
19-32: DASL HiCAP

 

 Niazi, T., S. Williams, I. D. Davis, M. R. Stockler, A. J. Martin, W. Hague, K. Bracken, M. Gorzeman, F. Roncolato, S. Yip, L. Horvath, S. Sengupta, S. Hughes, R. S. McDermott, J. WF. Catto, N. Vapiwala, W. R. Parulekar & C. Sweeney (2020). “DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer” Poster Presentation – ASCO Annual Meeting (J Clin Oncol 38, 2020 (no. 6 suppl; abstr TPS385)).
07-11: SCC Retreat

 

 Thirion, P., M. Dunne, I. Parker, C. Small, A. M. Shannon, A. Clayton-Lea, M. Parker, C. D. Collins, J. Coffey, N. Elbeltagi, D. Fitzpatrick, O. McArdle, M. Stevenson, A. Alvarez-Iglesias, M. Moriarty, O. Salib, C. Gillham, and J. G. Armstrong (2020). “Phase II Trial Evaluating Radiobiological Based Reirradiation Strategy for Patients with Malignant Spinal Cord Compression” Oral Presentation – ASTRO (Int J Radiat Oncol Biol Phys 108, issue 3, S33-34).

2019 Conference Presentations
15-21: ExPeCT

 

 Brady, L., B. Hayes, G. Sheill, A-M. Baird, E. M. Guinan, B. Stanfill, T. Vlajnic, O. Casey, J. P. Greene, E. Allott, J. M. Hussey, F. Cahill, M. Van Hemelrijck, N. Peat, S. M. Rudman, L. Mucci, O. Sheils, J. O’Leary, R. McDermott, S. P. Finn (2019). “The effect of a structured exercise intervention on CTCs and platelet cloaking in patients with metastatic prostate cancer.” Poster Presentation –ASCO GU (J Clin Oncol 37, 2019 (no. 7_suppl 243-243)).
15-49: NeoTRIP

 

 Gianni, L., C-S. Huang, D. Egle, B. Bermejo, C. Zamagni, M. Thill, A. Anton, S. Zambelli, G. Bianchini, S. Russo, E. Ciruelos, R. Greil, V. Semiglazov, M. Colleoni, C. Kelly, G. Mariani, L. Del Mastro, I. Maffeis, P. Valagussa and G. Viale. (2019). “Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study.” Oral Presentation- SABCS (abstr: GS3-04).
11-03: SOLE

 

 Jerusalem, G., S. Farah, J. Chirgwin, S. Aebi, P. Karlsson, P. Neven, E. Hitre, M-P. Graas, E. Simoncini, C. Kamby, A. Thompson, S. Loibl, J. Gavilá, K. Kuroi, C. Marth, B. Müller, S. O’Reilly, A. Gombos, T. Ruhstaller, H. Burstein, M. Rabaglio, B. Ruepp, G. Viale, R. D. Gelber, A. S. Coates, A. Di Leo, A. Goldhirsch, M. Regan and M. Colleoni. SOLE Investigators and International Breast Cancer Study Group, Bern, Switzerland (2019). “SOLE (study of letrozole extension), a phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC): Final analysis and sole estrogen substudy (SOLE-EST).” Poster Presentation- SABCS (abstr: P5-12-01).
15-02: PantHER

 

 Keegan, N. M., S. Furney, J. Walshe, G. Gullo, M. J. Kennedy, K. Bulger, J. McCaffrey, C. M. Kelly, K. Egan, J. Kerr, M. Given, P. O’Donovan, A. Hernando, A. Teiserskiene, I. Parker, E. Kay, A Farrelly, A. Carr, G. Calzaferri, R McDermott, M. M. Keane, L. Grogan, O. S. Breathnach, P. G.  Morris, S. Toomey, B. T. Hennessy (2019). “A phase Ib trial of copanlisib in combination with trastuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER.” Poster Presentation- SABCS (abstr: P1-19-24).
06-32: NSABP B42

 

 Mamounas, E. P.,  H. Bandos, B. C. Lembersky, J-H. Jeong, C. E. Jr Geyer, P. Rastogi, L. Fehrenbacher, M. L. Graham, S. K. Chia, A. M. Brufsky, J. M. Walshe, G. S. Soori, S. R. Dakhil, T. E. Seay, J. L III. Wade, E. C. McCarron, S. Paik, S. M. Swain, D. L. Wickerham and N. Wolmark (2019). “Ten-year results from NRG Oncology/NSABP B-42: A randomized, doubleblinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI).” Oral Presentation- SABCS (abstr: GS4-01).
12-30: TailorX Tissue Bank

 

 O’Connor, D., C. M. Kelly, J. Crown, N. Russell, S. Barron, T. Loughman, S. Lynch, A. O’Grady, K. M. Sheehan, J. Fay, A. Saha, P. Dynoodt, B. Fender, C-J. A. Wang, D. O’Leary, A. P. Bracken, A. Rahman, C. A. Gonzalez, N. Al Attar, W. M. Gallagher (2019). “Additional prognostic value of OncoMasTR multigene prognostic signature to clinicopathological information in patients with HR-positive, HER2-negative, lymph node-negative breast cancer from the TAILORx Tissue Bank, Ireland.” Poster Presentation-ASCO General Meeting (J Clin Oncol 37, 2019 (suppl; abstr 535)).
15-21: ExPeCT

 

 Sheill, G., L. Brady, E. M. Guinan, J. M. Hussey, B. Hayes, A-M. Baird, B. Stanfill, O. Casey, V. Murphy, S. M. Rudman, N. Peat, O. Sheils, F. Cahill, M. Van Hemelrijck, J. McCaffrey, D. M. O’Donnell, L. Mucci, W. Grogan, R. McDermott, S. P. Finn, The ExPeCT Research Group (2019). “A randomized trial of exercise on quality of life in men with metastatic prostate cancer: The ExPeCT Trial.” Poster Presentation –ASCO Supportive Care in Oncology Symposium (J Clin Oncol 37, 2019 (no. 31_suppl 97-97)).
14-06: ENZAMET STUDY

 

 Sweeney, C., A. J. Martin, R. R. Zielinski, A. Thomson, T. H. Tan, S. K. Sandhu, M. N. Reaume, D. W. Pook, F. Parnis, S. A. North, R. McDermott, J. McCaffrey, G. M. Marx, N. J. Lawrence, L. Horvath, M. Frydenberg, S. Chowdhury, K. N. Chi, M. R. Stockler, I. D. Davis (2019). “Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.” Oral Presentation-ASCO General Meeting (J Clin Oncol 37, 2019 (suppl; abstr LBA2)).

2018 Conference Presentations
12-16: Angiopredict

 

 Barat, A., D. Smeets, B. Moran, S. Das, J. Betge, V. Murphy, E. Kay, N. C. T. van Grieken, H. M. W. Verheul, T. Gaiser, M. P. Ebert, N. Schulte, B. Hennessy, W. M. Gallagher, D. A. McNamara, B. Ylstra, D. Lambrechts, D. O’Connor, A. T. Byrne, J. Prehn (2018). “A machine-learning approach for the identification of highly predictive germline SNPs as biomarkers for response to bevacizumab in metastatic colorectal cancer using Elastic Net and Lasso” Poster Presentation- ASCO Annual Meeting (J Clin Oncol 36, 2018 (no. 15 suppl; abstr e15584)).
12-40: EORTC 10085

 

 Bayani, J., C. Poncet, C. Q. Yao, C. Crozier, N. Anouk, T. Piper, C. Cunningham, M. Sobol, S. Aebi, K. Benstead, O. Bogler, L. Dal Lago, J.  Fraser, F. H. Hilbers, I. Hedenfalk, L. Korde, B. Linderholm, J. Martens, L. Middleton, M. Murray, C. Kelly, C. Nilsson, M. Nowaczyk, S. Peeters, A. Peric, P. Porter, C. Schröder, I. T. Rubio, K. J. Ruddy, C. van Asperen, D. Van Den Weyngaert, C. van Deurzen, E. van Leeuwen-Stok, J. Vermeij, E. Winer, P. C. Boutros, S. H. Giordano, F. Cardoso and J. M. Bartlett (2018). “Evaluation of multiple transcriptomic gene risk signatures in male breast cancer” Poster Presentation – SABCS (abstr P6-19-01).
14-13: MSD  MK-3475-024/ KEYNOTE-024 Brahmer, J., D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, A. Riccio, J. Yang, M. C. Pietanza, M. Reck (2018). “PS3 KEYNOTE-024 Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC with PD-L1 Tumor Proportion Score ≥50%” Oral Presentation – IASLC (J Thorac Oncol 13, no 9 suppl; abstr PS3).
10-04/11-24: NSABP B46/ NSABP B47

 

 Crown, J., J. M. Walshe, D. W. Fennelly, J.-C. Long, J. Ballot, D. McDonnell, S. Cairney, T. Lyons, A. O’Meara, C. Buckley, J. Gannon, M. Quinn, G. Gullo (2018). “Incidence of long-term hair loss (LHL) following docetaxel (D)-containing non-anthracycline (A) adjuvant chemotherapy (Adj) of early stage breast cancer (ESB)” Poster Presentation- ASCO Annual Meeting (J Clin Oncol 36, 2018 (no. 15 suppl; abstr e12522)).
12-24: ETOP BELIEF

 

 Curioni, A., E. Felip, U. Dafni, M-A. Molina, O. Gautschi, S. Peters, B. Massutí, R. Palmero, S. P. Ponce, E. Carcereny, M. Früh, M. Pless, S. Popat, S. Cuffe, N. Karachaliou, R. Kammler, M. Kassapian, H. Roschitzki-Voser, R. A. Stahel, R. Rosell (2018). “Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial” Poster Presentation – ESMO (Ann Oncol 29, no 8 suppl; abstr 1422P).
15-34: Recurrence Score

 

 Hassan, A (2018). “The Impact of the 21 Gene Recurrence Score on Chemotherapy Prescribing in Estrogen Receptor Positive, Lymph Node Positive Early-Stage Breast Cancer in Ireland: A National, Multi-centre, Prospective Study (CTRIAL-IE 15-34)” Poster Presentation– ISMO Annual Meeting.
17-13: Panthera

 

 Hassan, A., G. Gullo, S. O’Reilly, M. Ruiz- Borrego, S. Toomey, L. Grogan, O. Breathnach, P. G. Morris, J. M. Walshe, J. Crown, D. O’Mahony, A. Falcon, K. Egan, A. Hernando, A. Teiserskiene, C. M. Kelly, L. Coate and B. T. Hennessy (2018). “Phase Ib clinical trial of coPANlisib in combination with Trastuzumab emtansine (T-DM1) in pre-treated unresectable locally advanced or metastatic HER2-positive breAst cancer (BC) “PANTHERA”-CTRIAL-IE 17-13” Poster Presentation- SABCS (abstr OT3-06-01).
15-34: Recurrence Score

 

 Hassan, A., N. Keegan, C. O’Leary, L. McSorley, T. Mahgoub, S. O’Reilly, J. Walshe, M. J. Kennedy, L. Coate, M. O’Connor, M. Keane, C. M. Kelly, M. Milewski, S. Molloy, K. Eagan, V. Murphy, O. S. Breathnach, L. Grogan, B. Hennessy, P. G. Morris (2018). “The impact of the 21 gene recurrence score (RS) on chemotherapy (CHemoRx) prescribing in hormone receptor (HR) positive, lymph node positive (LN+) early-stage breast cancer (BC) in Ireland: A national, multi-centre, prospective study (CTRIAL-IE 15-34)” Poster Presentation – ESMO (Ann Oncol 29, no 8 suppl; abstr 208P).
15-02: PantHER

 

 Keegan, N. M., J. M. Walshe, S. Toomey, G. Gullo, M. J. Kennedy, K. N. Bulger, J. McCaffrey, C. M. Kelly, J. Crown, K. Egan, J. Kerr, A. Teiserskiene, A. Hernando, I. Parker, R. McDermott, M. M. Keane, W. Grogan, O. S. Breathnach, P. G. Morris, B. Hennessy (2018). “A phase Ib trial of copanlisib and tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer ‘PantHER’” Poster Presentation – Poster Presentation- ASCO Annual Meeting (J Clin Oncol 36, 2018 (no. 15 suppl; abstr 1036)).
15-02: PantHER

 

 Keegan, N., S. Toomey, A. Farrelly, A. Carr, G. Calzaferri, J. Walshe, G. Gullo, J. P. Crown, K. Egan, A. Hernando, A. Teiserskiene, L. Grogan, O. S. Breathnach, P. G. Morris, B. Hennessy (2018). “Monitoring the effect of PI3K inhibition on HER2 therapy resistant breast cancer using serial analysis of PIK3CA mutant tumour DNA in plasma” ESMO (Ann Oncol 29, no 8 suppl; abstr 138P).
12-30: TAILORx Tissue Bank

 

 Kelly, C. M., J. Crown, N. Russell, S. Barron, S. Lynch, A. O’Grady, K. Sheehan, J. Fay, V. Amberger-Murphy, A. Saha, T. Loughman, P. Dynoodt, B. Fender, C. Lopez Ruiz, C-J. A. Wang, D. O’Leary, D. O’Connor, W. M. Gallagher (2018). “Comparison of the prognostic performance between OncoMasTR and OncotypeDX multigene signatures in hormone receptor-positive, HER2-negative, lymph node-negative breast cancer” Poster Presentation- ASCO Annual Meeting (J Clin Oncol 36, 2018 (no. 15 suppl; abstr 12074).
13-21: Radium-223 & Enzalutamide mCRPC Study McDermott, R. S., J. P. Greene, O. Deignan, J. McCaffrey, I. Parker, A. Bowes, A. Teiserskiene, J. Feeney, P. G. Thirion, S. P. Finn, P.  J. Kelly (2018). “Phase II safety and tolerability study of Radium-223 (R223) in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CTRIAL-IE (ICORG) 13-21” Poster Presentation- ASCO Annual Meeting (J Clin Oncol 36, 2018 (no. 15 suppl; abstr 5050).
12-39 De-ESCALaTE HPV Head & Neck

 

 Mehanna, H., A. Kong, A. Hartley, P. Mistry, M. Dalby, T. Fulton-Lieuw, M. Robinson, A. Gray, B. Foran, M. Sen, L. O’Toole, K. Dyker, H. Al Booz, R. Moleron, S. Brennan, E. Aynsley, A. Chan, D. Srinivasan, J. Buter, J. Dunn (2018). “Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy” Oral Presentation – ESMO (Ann Oncol 29, no 8 suppl; abstr LBA9_PR).
12-53: ETOP SPLENDOUR

 

 Peters, S., S. J. Danson, B. Hasan, N. Reinmuth, M. Majem, K. G. Tournoy, M. T. Mark, M. Pless, M. Cobo, D. Rodriguez-Abreu, L. Falchero, B. Massutí, L. Coate, R. von Moos, C. Zielinski, E. De Maio, M. O’Brien, H. Roschitzki-Voser, U. Dafni, R. Stahel (2018). “A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC – the ETOP and EORTC SPLENDOUR trial” Poster Presentation – ESMO (Ann Oncol 29, no 8 suppl; abstr 1385PD). 
12-43: TRIO 022 Rugo, H. S., R. S. Finn, K. A. Gelmon, A. A. Joy, O. N. Lipatov, N. Harbeck, A. Castrellon, H. Mukai, J. M. Walshe, A. Mori, E. Gauthier, D. R. Lu, E. Bananis, M. Martın, V. Dieras (2018). “Clinical outcomes in patients (pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2” Poster Presentation – ESMO (Ann Oncol 29, no 8 suppl; abstr 332P).
06-31: TAILORx Sparano, J. A., R. J. Gray, W. C. Wood, D. F., Makower, T. G. Lively, T. J. Saphner, M. M. Keane, H. L. Gomez, P. S. Reddy, T. F. Goggins, I. A. Mayer, D. Toppmeyer, A. Brufsky, M. P. Goetz, D. F. Hayes, E. C. Dees, K. I. Pritchard, C. E. Geyer, J. A. Olson, and G. W. Sledge (2018). “TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.” Oral Presentation- ASCO Annual Meeting (J Clin Oncol 36, 2018 (no. 18 suppl; abstr LBA1).
12-38: TRI-LARC

 

 Toomey, S., A. Sartori, D. Irwin, S. Hummel, A. Carr, C. L. Lee, P. Armstrong, A. Farrelly, S. El-Masry, D. McNamara, P. G. Morris, L. Grogan, O. S. Breathnach, L. O’Sullivan, S. Bradshaw, A. N. A. M. Rashed, R. Smyth, J. Workman, B. O’Neill, B. Hennessy (2018). “Non-invasive genotyping and monitoring of tumor evolution in locally advanced rectal cancer (LARC) patients using circulating tumor DNA (ctDNA)” Poster Presentation – ESMO (Ann Oncol 29, no 8 suppl; abstr 551P).
09-03: AVO-OVA 16 (GSK: VEG110655) Vergote, I., L. C. Hanker, A. Floquet, J. Rau, J-W. Kim, E. O. Izquierdo, M. Friedlander, S. Pignata, K. Fujiwara, N. Colombo, M. R. Mirza, B. J. Monk, M. Mörtl, P. Calvert, T.  J. Herzog, C. Jackisch, J. Meunier, J-Y. Lee, A. K. Belau, A. Du Bois (2018). “AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results” Poster Presentation- ASCO Annual Meeting (J Clin Oncol 36, 2018 (no. 15 suppl; abstr 5518).
16-60: CLL13 Von Tresckow J., C. Niemann, A. P. Kater, J. Bahlo, M. Fürstenau, A.-M. Fink, M. Gregor, P. Thornton, T. Tadmor, K. Fischer, M. Ritgen, K. A. Kreuzer, E. Eldering, S. Stilgenbauer, M. Van Oers, C. Geisler, M. J. Hallek, B. Eichhorst (2018). “The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL).” Poster Presentation- ASCO Annual Meeting (J Clin Oncol 36, 2018 (no. 15 suppl; abstr TPS7582).
10-14/ 12-38: Neo-AEGIS/ TRI-LARC

 

 Wallace, N., C. Skourou, B. O’Neill, L. O’Sullivan, S. French, M. Cunningham (2018). “Optimising radiation therapy quality assurance (RTQA) in Irish oncology trials” Poster Presentation- ESTRO (37, abstr EP-2164).
10-14/ 12-38: Neo-AEGIS/ TRI-LARC

 

 Wallace, N., C. Skourou, J. Gaffney, L. O’Sullivan, S. French, M. Cunningham, J. Reynolds, B. O’Neill (2018). “Optimising radiation therapy quality assurance (RTQA) in Irish oncology trials” Poster Presentation- Faculty of Radiologists Annual Scientific Meeting, RCSI.